OCUL Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Company profile

Antony Mattessich
Fiscal year end
Former names

OCUL stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


5 May 21
18 May 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 211.14M 211.14M 211.14M 211.14M 211.14M 211.14M
Cash burn (monthly) 6.23M (positive/no burn) 6.74M 5.54M 5.79M 4.34M
Cash used (since last report) 9.87M n/a 10.69M 8.78M 9.17M 6.88M
Cash remaining 201.27M n/a 200.45M 202.36M 201.97M 204.26M
Runway (months of cash) 32.3 n/a 29.7 36.5 34.9 47.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
17 Feb 21 Donald Notman Stock Option Common Stock Grant Aquire A No No 18.31 190,000 3.48M 190,000
17 Feb 21 Antony C. Mattessich Stock Option Common Stock Grant Aquire A No No 18.31 455,000 8.33M 455,000
17 Feb 21 Patricia Kitchen Stock Option Common Stock Grant Aquire A No No 18.31 220,000 4.03M 220,000
17 Feb 21 Michael H. Goldstein Stock Option Common Stock Grant Aquire A No No 18.31 250,000 4.58M 250,000
17 Feb 21 Philip C. Strassburger Stock Option Common Stock Grant Aquire A No No 18.31 51,900 950.29K 51,900

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

66.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 150 108 +38.9%
Opened positions 55 18 +205.6%
Closed positions 13 17 -23.5%
Increased positions 48 39 +23.1%
Reduced positions 35 30 +16.7%
13F shares
Current Prev Q Change
Total value 1.35B 411.28M +228.3%
Total shares 50.38M 39.78M +26.7%
Total puts 198.3K 238.7K -16.9%
Total calls 508K 200.7K +153.1%
Total put/call ratio 0.4 1.2 -67.2%
Largest owners
Shares Value Change
Opaleye Management 6.51M $134.76M +8.8%
Summer Road 5.62M $116.31M +0.0%
BLK Blackrock 5.51M $114.1M +35.0%
Vanguard 3.55M $73.49M +19.2%
Deltec Asset Management 2.17M $44.89M -12.3%
Citadel Advisors 1.59M $32.89M -2.0%
Versant Venture Management 1.47M $30.33M -33.9%
STT State Street 1.45M $30.12M +26.6%
Emerald Advisers 1.19M $24.65M NEW
Emerald Mutual Fund Advisers Trust 1.12M $23.22M NEW
Largest transactions
Shares Bought/sold Change
Ra Capital Management 750K -1.98M -72.5%
BLK Blackrock 5.51M +1.43M +35.0%
Emerald Advisers 1.19M +1.19M NEW
Emerald Mutual Fund Advisers Trust 1.12M +1.12M NEW
Victory Capital Management 1.09M +1.09M NEW
Ikarian Capital 684.57K -1.03M -60.1%
Great Point Partners 856.16K +856.16K NEW
Driehaus Capital Management 839.91K +839.91K NEW
IVZ Invesco 1M +811.06K +427.2%
D. E. Shaw & Co. 1.05M +776.76K +284.5%

Financial report summary

Management Discussion
  • We are a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye using our proprietary, bioresorbable hydrogel platform technology. We use this technology to tailor duration and amount of delivery of a range of therapeutic agents in our product candidates.
  • We currently incorporate therapeutic agents that have previously received regulatory approval from the U.S. Food and Drug Administration, or FDA, including small molecules and proteins, into our hydrogel technology with the goal of providing local programmed-release of drug to the eye. We believe that our local programmed-release drug delivery technology has the potential to treat conditions and diseases of both the front and the back of the eye and can be administered through a range of different modalities including intravitreal implants, suprachoroidal implants, intracameral implants and intracanalicular inserts. We have product candidates in preclinical and clinical development designed to utilize this technology to treat retinal diseases including wet age-related macular degeneration, or wet AMD; glaucoma and ocular hypertension; and ocular surface diseases and conditions including chronic and acute dry eye disease and ocular itching associated with allergic conjunctivitis. We also have two FDA-approved products in commercialization in the United States: DEXTENZA®, an intracanalicular insert for the treatment of post-surgical ocular inflammation and pain, and ReSure® Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. Our core pipeline assets include four development programs. We are currently evaluating two of these programs in Phase 1 clinical trials: OTX-TKI, an intravitreal implant injected by fine-gauge needle of a hydrogel, anti-angiogenic formulation of axitinib, a tyrosine kinase inhibitor, or TKI, for the treatment of wet AMD, and OTX-TIC, a travoprost intracameral implant for the reduction of intraocular pressure, or IOP, in patients with primary open-angle glaucoma or ocular hypertension. We have commenced Phase 2 clinical trials of OTX-CSI, a cyclosporine intracanalicular insert for the chronic treatment of dry eye disease, and OTX-DED, a dexamethasone intracanalicular insert for the short-term treatment of the signs and symptoms of dry eye disease.
  • We also have a collaboration with Regeneron Pharmaceuticals, Inc., or Regeneron, for the development and potential commercialization of products containing our extended-delivery hydrogel in combination with Regeneron’s large molecule vascular endothelial growth factor, or VEGF, inhibitor, aflibercept, currently marketed under the brand name Eylea. On May 8, 2020, we entered into an amendment to our existing collaboration agreement with Regeneron. Pursuant to this amendment, we and Regeneron have adopted a new workplan to transition joint efforts under the existing collaboration agreement to the research and development of an extended-delivery formulation of aflibercept to be delivered to the suprachoroidal space. Regeneron has agreed to pay for our personnel and material costs for specified preclinical development activities in connection with the revised workplan, as well as costs of certain specialty equipment.
Content analysis
H.S. junior Avg
New words: affiliate, affiliated, Allergan, ASEAN, Asia, Benchmark, Biden, biometric, Brunei, Cambodia, CCPA, comparison, convey, Cooperation, Coughenour, depth, DER, destruction, distributor, Dr, drew, Durysta, EEA, eIND, eluting, engineering, exploit, expressed, FCA, furlough, gathered, genetic, hear, IFU, improperly, Indonesia, injector, introduced, Kevin, lamp, lapse, lieu, Malaysia, married, mechanism, memo, modest, Myanmar, nationwide, onsite, opt, overturning, Ozden, Pharma, prepay, prepayment, presidential, prevail, pronounced, Rabia, rapid, reconsider, recovery, refinance, reprioritize, Road, salary, salesforce, Senate, sequester, shut, shutdown, Singapore, SISPQ, slit, standalone, steroid, Summer, Thailand, threat, traditional, trillion, undermine, unpatentability, unregistered, vaccination, Vice, Vietnam, wholesaler, withdrew, Wong
Removed: accomplish, acknowledged, adapt, addressable, adherence, adjusting, administering, ads, affirming, afternoon, age, AgreementSM, al, alleged, allegedly, allergen, Angel, annualized, appointed, approximate, argued, assumed, avoid, avoidance, belted, bifurcation, billing, billion, biodegraded, blueprint, bona, boost, borrow, Brian, buying, cac, calculating, Cantor, captioned, Caraker, carrier, Century, channel, charge, Chargeback, circumvent, clarification, clarify, clarifying, classification, Codification, Commonwealth, complaint, component, comprised, computed, computing, concept, conclusion, constituted, constrained, construction, constructive, construed, context, conversation, coordinate, corridor, Corwin, County, dashboard, deadline, declaratory, deducting, degrading, delaying, deny, deposit, designate, discontinued, dismissal, disorder, distinct, diurnal, dividing, docket, doubt, Dutch, duty, Dylan, electorate, emergent, enrichment, episodic, equitable, escalation, estate, examine, exceeded, excessive, expedient, extendable, eyelid, familiar, FAS, feel, feet, fide, fiduciary, finalizing, fixed, formulated, frequently, gag, Gallagher, gaming, geographic, heard, Hg, HHS, hired, host, humor, Importantly, improving, incentivize, inclusion, IND, indemnification, informing, innovation, intention, Interaction, intraperiod, invoice, IPO, irrevocably, ITT, iv, Jersey, Jumpstart, KAM, Kelly, Kim, lacrimal, landlord, lawsuit, leading, leased, leaving, left, lien, Life, liquidate, localized, LOCF, lowering, Madera, magistrate, manager, mandated, mercury, Minister, mishandling, mismanagement, mm, mmHg, modernize, morning, motion, negotiating, negotiation, neutrality, notable, noted, noticeable, OMB, opening, oppose, Ora, ordered, ordinarily, owed, package, participant, participating, paused, perennial, peripheral, perpetual, pharmacodynamic, pilot, plaintiff, plug, poor, posted, precluded, premised, preservation, principle, problematic, productive, promised, proof, proportion, proposal, punctal, punctum, purported, putative, quantity, randomization, ranged, real, realization, reallocate, reallocation, rebound, recoverability, Refractive, regimen, region, regular, released, relying, repair, replacement, reply, represented, resale, rescue, restraining, resume, returned, reversal, revoked, Robert, Robinson, Sawhney, seal, seasonal, session, Shawna, Shipment, simplify, Society, speed, spoilage, spur, square, stating, stay, staying, stipulation, stringent, studied, Subfield, sublease, substitute, substituting, substitution, successive, Suffolk, superiority, surrendered, SV, synechiae, Task, terminating, Terry, thereunder, thirteen, timepoint, timolol, tissue, tolerated, Topic, trailing, transit, UK, underwriter, underwriting, undistributed, unfairly, unjust, unlimited, unopposed, unspecified, unvested, vacant, vacated, vigorously, voted, washout, wrongdoing